Interleukin-3 Receptor alpha Subunit
"Interleukin-3 Receptor alpha Subunit" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A low affinity interleukin-3 receptor subunit that combines with the CYTOKINE RECEPTOR COMMON BETA SUBUNIT to form a high affinity receptor for INTERLEUKIN-3.
Descriptor ID |
D053650
|
MeSH Number(s) |
D12.776.543.750.705.852.420.340.500
|
Concept/Terms |
Interleukin-3 Receptor alpha Subunit- Interleukin-3 Receptor alpha Subunit
- Interleukin 3 Receptor alpha Subunit
- Interleukin-3 Receptor alpha Chain
- Interleukin 3 Receptor alpha Chain
- Antigens, CD123
- CD123 Antigens
- alpha-Subunit, Receptor, Interleukin-3
- CD123 Antigen
- Antigen, CD123
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-3 Receptor alpha Subunit".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-3 Receptor alpha Subunit".
This graph shows the total number of publications written about "Interleukin-3 Receptor alpha Subunit" by people in this website by year, and whether "Interleukin-3 Receptor alpha Subunit" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2008 | 1 | 0 | 1 |
2013 | 1 | 0 | 1 |
2014 | 0 | 1 | 1 |
2016 | 3 | 0 | 3 |
2017 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
2019 | 1 | 2 | 3 |
2020 | 3 | 2 | 5 |
2021 | 0 | 4 | 4 |
2022 | 1 | 5 | 6 |
2023 | 0 | 6 | 6 |
2024 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-3 Receptor alpha Subunit" by people in Profiles.
-
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123. Leuk Res. 2024 04; 139:107479.
-
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study. Lancet Oncol. 2024 Mar; 25(3):388-399.
-
Phase 1b trial of tagraxofusp in combination with azacitidine with or without venetoclax in acute myeloid leukemia. Blood Adv. 2024 02 13; 8(3):591-602.
-
Peptide-scFv antigen recognition domains effectively confer CAR T?cell multiantigen specificity. Cell Rep Med. 2024 Feb 20; 5(2):101422.
-
Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e130-e137.
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
-
Blastic plasmacytoid dendritic cell neoplasm: emerging developments and special considerations for 2023. Clin Adv Hematol Oncol. 2023 May; 21(5):257-264.
-
Improving the anti-acute myeloid leukemia activity of CD123-specific engager T cells by MyD88 and CD40 costimulation. Haematologica. 2023 04 01; 108(4):1039-1052.
-
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023 02 09; 141(6):567-578.
-
First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia. Clin Transl Sci. 2023 03; 16(3):429-435.